Endothelin and Skeletal Metastases in Hormone-Refractory Prostate Cancer

Author： Hamdy F.C.  

Publisher： Elsevier

ISSN： 1569-9056

Source： European Urology Supplements, Vol.2, Iss.3, 2003-03, pp. : 15-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of Endothelin in Hormone-Refractory Prostate Cancer

By Zonnenberg B.A.   Voest E.E.  

European Urology Supplements, Vol. 2, Iss. 3, 2003-03 ,pp. : 9-14

Elsevier

Access to resources Recommend Favorite

Atrasentan: The First Endothelin Receptor Antagonist for Hormone-Refractory Prostate Cancer

By Schulman C.  

European Urology Supplements, Vol. 2, Iss. 3, 2003-03 ,pp. : 20-27

Elsevier

Access to resources Recommend Favorite

Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy

By Malmberg I.   Persson U.   Ask A.   Tennvall J.   Abrahamsson P.-A.  

Urology, Vol. 50, Iss. 5, 1997-11 ,pp. : 747-753

Elsevier

Access to resources Recommend Favorite

Revolutions in the Management of Hormone-Refractory Prostate Cancer

By Abrahamsson P.-A.  

European Urology Supplements, Vol. 2, Iss. 3, 2003-03 ,pp. : 1-2

Elsevier

Access to resources Recommend Favorite

The Role of Urologists in the Management of Hormone-Refractory Prostate Cancer

By Pummer K.  

European Urology Supplements, Vol. 1, Iss. 2, 2002-05 ,pp. : 24-28

Elsevier

Access to resources Recommend Favorite